HomeAI · summaries
Storia in 3 fonti
Gilead, Merck Advance Potential Blockbuster Weekly HIV Pill - Merck & Co (NYSE:MRK), Gilead Sciences (NAS
Gilead & Merck Phase 3 data shows once-weekly ISL/LEN matches daily HIV meds in viral suppression through 48 weeks.
Confronto fonti
3 prospettive sulla stessa storiaTimeline cronologica
- ·
fiercepharma.com
Gilead, Merck’s phase 3 data back first weekly HIV pill
Detailed phase 3 results suggest the two-drug combination of Gilead Sciences’ lenacapavir and Merck & Co.’s islatravir has what it takes to become the first complete weekly pill…
- ·
endpoints.news
Gilead and Merck provide HIV data; Dimension Capital announces $800M fund
Gilead-Merck detail Phase 3 HIV data, Dimension Capital closes $800M fund, WuXi AppTec fights DoD blacklist bid, and more.
